hVIVO, a specialty biopharma company with clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. hVIVO changed its name from Retroscreen Virology in April 2015. The business is a plc quoted on the AIM London Stock Exchange (ticker ‘HVO’).
Focus Areas
Notable Investments
